Technical analysis of None (BLRX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer.
Price Performance
| 1 month | -12.98% |
| 3 months | -21.52% |
| Year-to-date | -10.47% |
| 1 year | -34.04% |
| 3 years | -96.92% |
| 5 years | -97.68% |
52-Week Range
| 52-week High | $4.56 |
| 52-week Low | $2.15 |
| Avg Volume (90d) | 40K |
Technical Indicators
| SMA 50 | $2.78 |
| SMA 200 | $2.87 |
| Beta | 0.48 |
| 30-day Volatility (annualised) | 58.2% |
| Price vs SMA 50 | -10.6% |
| Price vs SMA 200 | -13.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $3.47 | |
| 2025-11 | $3.47 | +0.0% |
| 2025-12 | $2.77 | -20.2% |
| 2026-01 | $3.11 | +12.3% |
| 2026-02 | $2.83 | -9.0% |
| 2026-03 | $2.30 | -18.7% |
| 2026-04 | $2.75 | +19.6% |
| 2026-05 | $3.78 | +37.5% |
| 2026-06 | $3.12 | -17.5% |
| 2026-07 | $2.82 | -9.6% |
| 2026-08 | $2.80 | -0.7% |
| 2026-09 | $2.48 | -11.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $2.48 |
| Market Cap | $11M |